AMBS FRIDAY GAZELLE PLAY Amarantus BioScience to Hold

New Post Public Reply Private Reply Replies (0) Message Board

Apr 5, 2013 at 8:47 AM

AMBS >>FRIDAY GAZELLE PLAY

Amarantus BioScience to Hold Business Update Conference Call on April 16

2013-04-05 08:00 ET - News Release

SUNNYVALE, Calif. -- (Business Wire)

Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it will hold a conference call on Tuesday, April 16, 2013 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to provide an update on its business and conduct a question and answer session with investors.

Individuals interested in listening to the conference call may do so by dialing 877-407-8033, or for international callers 201-689-8033. The call is also being webcast, and can be accessed from the Company’s Web site (www.amarantus.com) and at www.InvestorCalendar.com.

A telephone replay will be available through May 1, 2013 by dialing 877-660-6853, or for international callers 201-612-7415, and entering the Conference ID #: 411612. The webcast replay will be available for 90 days following the completion of the call.

During the call Amarantus Chief Executive Officer Gerald Commissiong will recap key accomplishments of 2012 and the first quarter of 2013, provide clarity on the Company’s recently updated business model and discuss business and product development initiatives planned for the remainder of 2013.

About Amarantus BioScience

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company is focused on developing unique products and proprietary technologies for the potential treatment and/or diagnosis of Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for neurological disorders where there is a significant unmet medical need. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and related nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson’s disease, as well as statements about expectations, plans and prospects of the development of Amarantus' diagnostic product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Contacts:

Investor/Media Contact
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com

Source: Amarantus BioScience, Inc.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fault Codes vs. Diagnosis: What's the Real Fix?

When a Blink Isn’t the Whole Story Ever sat in your car, watched that check engine light flicker on, and felt your heart drop? Yeah, we've all been there. But here’s the kicker: just ‘cause that little demon’s glowing doesn’t mean your mechanic’s got all the answers. That’s where this HelloNation article steps in, trying to shed some light on the difference...

Altitude+ and ViewLift Celebrate Record Fan Engagement

Fresh Off the Bench: Altitude+ Rises Picture this: you're cruising through October, watching the leaves fall and the puck drop, and here come Altitude+ and ViewLift boasting some record numbers. This ain't your everyday puff piece — they've got concrete results to back it up. Altitude+, charging into the 2026–27 NHL and NBA seasons, isn't just surviving; they're...

Venezuelan Crude Hits Texas: NABEP's Bold Move

Venezuelan Crude Docking in Texas Signals New Energy Dynamics Batten down the hatches, 'cause NABEP's Venezuelan crude has made a splashy arrival in Texas. We're talking 1 million barrels, folks, the first of its kind under a fresh U.S. deal. This ain't your grandpa's oil shipment from the Middle East that takes forever to get here—nope, this crude made a pit stop in...

Heart Attack vs. Cardiac Arrest: Know the Differences

Spotting the Crisis: Heart Attack or Cardiac Arrest? When your heart’s in trouble, knowing whether it’s a heart attack or cardiac arrest isn’t just some medical trivia—it could save a life. According to healthcare whiz Justin Doss from Beaumont, Texas, this difference can be the thin line between life and a dire outcome. What's the Deal with These Heart Events?...

Lincoln Educational Faces Class Action for Stock Drop

What's Gripping Lincoln Educational Services? You ever feel like you've stepped into a financial thriller with these education stocks? Well, Lincoln Educational Services (NASDAQ:LINC) is at the heart of one, facing the heat of a class action lawsuit filed by Bleichmar Fonti & Auld LLP. It's all about securities fraud—a dreaded term that no investor wants to hear. The...

Yuchai Eyes African Market Expansion with Strategic Visits

Yuchai's Bold Move into Africa There's something gutsy about a company that doesn't just sit on its achievements but heads out into new territories. China Yuchai International (NYSE: CYD), a big player in powertrain solutions, recently embarked on a strategic tour across the African continent, a move that could well shape their future market playbook. East Africa:...

Americans' Faith in Democracy Hits New Lows

Polarization Beyond Politics: A National Reckoning When you catch wind of a report like this one, it's enough to make you feel like the fabric of democracy is unraveling right before our eyes. We're staring at a national identity crisis, folks, and it's got nothing to do with whether you're waving a red or blue flag. This ain't about party lines; it's about a bigger,...

Franklin Financial Q3: 59% Net Income Surge Amid Growth

Soaring Net Income and Impressive Growth Franklin Financial Services Corporation (NASDAQ: FRAF) seems to be on a roll this year, painting a vivid picture of growth as they close out the third quarter of 2026. With a strong surge in net income—59.4% up from Q3 2025—this leadership in earnings is no fluke. Net Income and Earnings per Share Let's break it down: the...

Alpheus Explores LDH Kinetics as Glioblastoma Biomarker

Cracking Glioblastoma's Tough Shell Some days, you're slogging through numbers that don't add up, and other times, you stumble upon findings that just might change the game. Alpheus Medical, diving headfirst into the murky waters of glioblastoma, dropped some intriguing data at the ESMO Congress 2026. This isn't your usual round of clinical discoveries, folks. What...

Post University Expands with New Tech and Health Degrees

If you're looking to invest in an education with promising payoffs, you might look into what's cooking over at Post University. They've just dropped a bombshell of new programs sure to get some attention from tech heads and health nuts alike, and I can't help but think there's potential brewing here. New Academic Paths Emerge Post University isn't resting on its...